Esomeprazole Magnesium
NDC Package 76519-1173-3

11-digit billing NDC: 76519117303

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Esomeprazole Magnesium is 1.1 Treatment of Gastroesophageal Reflux Disease (GERD)Healing of Erosive EsophagitisEsomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. Marketed by H.j. Harkins Company, Inc., this product is identified by NDC 76519-1173 and is authorized under FDA application ANDA078279.

Identification & Billing

NDC Package Code
76519-1173-3
Package Description
30 CAPSULE, DELAYED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
76519117303
RxNorm Crosswalk
  • RxCUI: 606730 - esomeprazole magnesium 40 MG Delayed Release Oral Capsule
  • RxCUI: 606730 - esomeprazole 40 MG Delayed Release Oral Capsule
  • RxCUI: 606730 - esomeprazole 40 MG (as esomeprazole magnesium 44.5 MG) Delayed Release Oral Capsule

Clinical Specifications

Proprietary Name
Esomeprazole Magnesium
Dosage Form
-
Usage Information
1.1 Treatment of Gastroesophageal Reflux Disease (GERD)Healing of Erosive EsophagitisEsomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. In infants 1 month to less than 1 year, esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated GERD. Maintenance of Healing of Erosive EsophagitisEsomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux DiseaseEsomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older.1.2 Risk Reduction of NSAID-Associated Gastric UlcerEsomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.1.3 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer RecurrenceTriple Therapy (esomeprazole magnesium delayed-release capsules plus amoxicillin and clarithromycin):Esomeprazole magnesium delayed-release capsules, in combination with amoxicillin and clarithromycin, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Dosage and Administration (2) andClinical Studies (14)].In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the prescribing information for clarithromycin].1.4 Pathological Hypersecretory Conditions Including Zollinger-Ellison SyndromeEsomeprazole magnesium delayed-release capsule USP is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.

Regulatory & Marketing

Labeler Name
H.j. Harkins Company, Inc.
FDA Application #
ANDA078279
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-25-2019
Listing Expiration
12-31-2021
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 76519-1173-3 identifies a specific commercial package of 30 capsule, delayed release in 1 bottle of Esomeprazole Magnesium, labeled by H.j. Harkins Company, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by H.j. Harkins Company, Inc. on March 25, 2019. The current certification is valid through December 31, 2021.

How is this H.j. Harkins Company, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 76519117303. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
76519-1173-3
11-Digit CMS (5-4-2)
76519-1173-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.